CWM
NKTR icon

Compass Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Compass Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-133
Closed -$1.36K – 318
2025
Q1 		$1.36K Hold
133
– – ﹤0.01% 414
2024
Q4 		$1.86K Hold
133
– – ﹤0.01% 379
2024
Q3 		$2.6K Hold
133
– – ﹤0.01% 380
2024
Q2 		$2.48K Hold
133
– – ﹤0.01% 385
2024
Q1 		$1.87K Hold
133
– – ﹤0.01% 373
2023
Q4 		$1.13K Hold
133
– – ﹤0.01% 371
2023
Q3 		$1.19K Hold
133
– – ﹤0.01% 382
2023
Q2 		$1.15K Hold
133
– – ﹤0.01% 393
2023
Q1 		$1.41K Hold
133
– – ﹤0.01% 401
2022
Q4 		$4.52K Buy
+133
New +$6.44K ﹤0.01% 384

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Compass Wealth Management's NKTR Position: Q2 2025 in Review

Compass Wealth Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 133 shares — an estimated $1.36K sold.

Compass Wealth Management first reported a position in NKTR in Q4 2022 and held it in 10 quarters. The position peaked at $4.52K in Q4 2022. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Compass Wealth Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Compass Wealth Management sold 133 Nektar Therapeutics shares in Q2 2025, an estimated $1.36K.
  • Compass Wealth Management first reported a position in Nektar Therapeutics in Q4 2022 and held it in 10 quarters.
  • Compass Wealth Management's Nektar Therapeutics position peaked at $4.52K in Q4 2022.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Compass Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.